Earnings call transcript: Zealand Pharma Q1 2026 sees stock surge By Investing.com

Zealand Pharma posted Q1 2026 revenue of DKK 34 million, with shares rising 11.89% to DKK 355.35 after the earnings release. Management reaffirmed 2026 operating expense guidance of DKK 2.7 billion-DKK 3.3 billion and raised collaboration revenue guidance to DKK 4.5 billion, while also announcing a $200 million buyback. The company highlighted strong liquidity at DKK 14.5 billion and expected 2026 liquidity of DKK 19 billion, supported by Roche milestone payments and advancing petrelintide into phase III.

Analysis

The key signal is not the quarter itself but the de-risking of the financing bridge into the next 12-18 months. With partner cash now visibly front-loaded and buybacks initiated while R&D intensity remains high, the market is starting to price Zealand less like a binary biotech and more like a self-funding platform with multiple shots on goal. That usually compresses the left tail: once a name is no longer dependent on external capital, every positive clinical update tends to re-rate faster because dilution risk falls out of the model.

The second-order effect is competitive positioning in obesity. A tolerability-first profile, if confirmed, changes the go-to-market debate from “who has the largest peak efficacy” to “who can retain patients long enough to matter,” which is a materially better commercial problem in a market already showing high discontinuation and payer pushback. That favors a differentiated amylin-led strategy and puts pressure on single-mechanism players that rely on pure efficacy to justify premium pricing.

The underappreciated catalyst path is the next 2-4 quarters: ADA data, phase III initiation, and the first meaningful read on combination utility. The main reverse-risk is not safety alone; it is any evidence that the efficacy plateau is more modest once the program is optimized for a real phase III population, or that maintenance dynamics disappoint. If that happens, the market could quickly reclassify the current move as a valuation pull-forward rather than a durable rerating.

Contrarian angle: the biggest misread may be the buyback. In biotech, repurchases often get treated as a return-of-capital signal, but here it is also management’s way of broadcasting confidence that internal IRR on pipeline investment exceeds the cost of capital. That tends to attract longer-duration capital, but it also means the stock can become crowded on good news; upside may be strongest into catalyst windows, while post-event digestion could be sharp if expectations outrun data quality.

Key Decisions for Investors

• Long Zealand Pharma (ZEAL) into ADA and phase III initiation; best risk/reward is 4-8 week momentum capture with asymmetric upside if tolerability/maintenance data confirm the thesis. Stop if full-data presentation shows no meaningful differentiation vs comparable obesity peers.
• Buy ZEAL call spreads expiring after the next major clinical readout; structure for catalyst-driven upside while limiting premium burn if the stock has already priced in optimism.
• Pair trade: long ZEAL / short a higher-beta obesity name with more dependence on pure efficacy and less on tolerability retention. The spread should work if the market continues to reward differentiation over headline weight-loss maxima.
• Take profits into ADA if the stock rerates ahead of full data by another 10-15%; the setup has clear event risk and the biggest drawdown often comes after the narrative is confirmed rather than before.
• For conservative portfolios, wait for confirmation of phase III design and maintenance strategy before adding size; the current move is supportive, but the next leg depends on execution, not sentiment.